CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: September-01-09
Credit Expiration Date: September-01-10


Medical Director
Shiley Center for Orthopaedic Research and Education at Scripps Clinic
La Jolla, CA

Medication Safety Officer
Brigham and Womenís Hospital
Boston, MA

Clinical Professor of Orthopaedic Surgery
Medical University of South Carolina
Chairman, Department of Orthopaedic Surgery
Roper Hospital
Charleston, SC

Credit Hours

Physicians: 1.25 credit hours
Nurses: 1.25 contact hours (0.125 CEU)
Pharmacists: 1.25 contact hours (0.125 CEU)



Program Description

Venous thromboembolism (VTE) is the most common preventable cause of hospital death in the United States, and patients undergoing major orthopedic surgery (eg, hip or knee arthroplasty) are among those at highest risk. Guidelines were published by the American College of Chest Physicians (ACCP) in 2008 which focus on prevention of VTE in orthopedic surgery , and guidelines were developed on the prevention of symptomatic pulmonary embolism (PE) by the American Academy of Orthopedic Surgeons (AAOS) in 2007. Despite the availability of these evidence-based guidelines, many barriers to implementation of appropriate VTE prophylaxis remain.

Findings from recent clinical research can provide clinicians with clarification about the optimal current and emerging prophylactic strategies. Efforts to assess VTE risk and apply existing evidence-based guidelines for VTE prophylaxis in orthopedic surgery patients can improve patient care and outcomes.

Program Developer/Facilitator


Target Audience

This educational activity is designed for orthopaedic surgeons, hospitalists, hospital-based internal medicine physicians, hospital system pharmacists, orthopaedic surgery nurses, and other healthcare professionals involved in the treatment of patients undergoing elective total hip or knee arthroplasty

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Review guidelines, consensus standards, and requirements for venous thromboembolism (VTE) prophylaxis in total hip arthroplasty (THA) and total knee arthroplasty (TKA) patients.
  2. Evaluate how to apply the latest clinical practice guidelines on the prevention of VTE for patients who undergo THA and TKA.
  3. Assess the safety and efficacy of existing and emerging anticoagulants for the prevention of VTE.
  4. Discuss how emerging oral anticoagulants may impact the prevention of VTE in THA and TKA patients.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

This educational activity may contain discussion of published and/or investigational treatments used in the management of venous thromboembolism (VTE). Some uses may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

CLIFFORD W. COLWELL, JR., MD, discloses that he served as a consultant for Bayer Healthcare and has received research support from Medical Compression Systems, Bayer Healthcare, and Boehringer Ingelheim.

KAREN FIUMARA, RPh, PharmD, indicates no actual or potential conflict of interest with regard to this program.

RICHARD J. FRIEDMAN, MD, FRCSC, discloses that he has received research support from Boehringer Ingelheim and Astellas Pharma US; is a sanofi-aventis speakerís bureau member; and is a consultant to Johnson & Johnson, DJO Surgical, Astellas Pharma US, and Boehringer Ingelheim. Dr. Friedman has held stock in Bayer Healthcare and Johnson & Johnson in the previous 12 months.

Credit Statements

Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc. designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Creditsô. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Centerís COA.
AKH Inc. designates this educational activity for 1.25 contact hours (0.125 CEU). Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA.

Pharmacists: AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. AKH Inc. approves this application-based activity for 1.25 contact hours (0.125 CEU). UAN 077-999-09-046-H01-P

Commercial Support Statements

This activity is supported through an educational grant from Ortho-McNeil Inc.

Certificate Fee



© 2009, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Ortho-McNeil Inc. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other healthcare professionals without first evaluating their patientsí conditions, considering possible contraindications or risks, reviewing any applicable manufacturerís product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu